Olympus today announced it commercially launched its Hanarostent esophagus TTS self-expanding metal stents.
The through-the-scope esophageal stent helps with luminal patency in a variety of clinical applications. It is designed for use in the palliative treatment of esophageal stricture or trachea-esophageal fistula caused by malignant tumors.
“From the first cases in which I’ve used it, I found the Hanarostent Esophagus TTS stent to effectively palliate the symptoms of our patients with advanced esophageal cancer,” Dr. Sandeep Patel, a gastroenterologist at UT Health San Antonio, said in a news release. “The hook-cross nitinol design of the TTS stents allows for accurate and efficient placement with increased patient comfort.”
Hanarostent Esophagus TTS fits in the working channel of a standard therapeutic gastroscope and is deployed for placement in the esophagus. It features a hook-and-cross nitinol design to enable optimal radial and axial force, allowing flexibility to conform to unique patient anatomies and precisely target strictures.
“We are pleased with the positive clinical feedback we have received from our trusted physician customers since our limited launch of Hanarostent esophagus TTS in July,” VP of endoscopy Kevin Mancini said. “We are confident the Hanarostent Esophagus TTS will help our physician customers address quality of life issues in patients suffering from advanced gastrointestinal disease.”
The stents are made by M.I. Tech and distributed exclusively through Olympus in the U.S.
“Through our valued partnership with Olympus, the Hanarostent esophagus TTS is the sixth stent successfully launched in the U.S. market in the past two years,” M.I. Tech CEO Jin-Hyung Park said. “We are thrilled to continue expanding capabilities of physicians in the U.S. and across the world, through the combination of a line of unparalleled stents and the trusted Olympus brand.”
